Drug Firms Have More Time For First Annual Report On Production Volumes US Is Requiring
Executive Summary
FDA announces day before due date that as it continues considering comments to a draft guidance on the requirement it published in October, the “document is not a binding document” and “the recommended … reporting date for 2020 data is not a requirement.”
You may also be interested in...
Annual Report With Monthly Production Totals Added To OTC Monograph Drug Firms' To-Do List
Firms making drugs available in US without pre-market approval, including homeopathics, got another annual reporting requirement under CARES Act. “It's going to be a bit of a sea change for the industry, and they're going to need to be prepared for it,” says attorney Ann Begley.
How US FDA Wants Pharmaceutical Production Volumes Reported For Drug Shortage Prevention
Monthly data are expected in annual reports on listed drugs and active ingredients from every registered site, starting in February.
US OTC Monograph FY2022 Facility Fees Deadline In June At Amount TBD
Firms making OTC monograph drugs won’t have to pay facility fees twice during FY2021, says Theresa Michele, FDA Office of Nonprescription Drugs director.